Yubin Ge

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6582004/publications.pdf

Version: 2024-02-01

128	4,921	76196	114278
papers	citations	40	63
		h-index	g-index

128	128	128	6624
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Clinical Cancer Research, 2016, 22, 4440-4451.	3.2	176
2	Binuclear Metal Centers in Plant Purple Acid Phosphatases: Feâ€“Mn in Sweet Potato and Feâ€“Zn in Soybean. Archives of Biochemistry and Biophysics, 1999, 370, 183-189.	1.4	161
3	Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. Journal of Cellular Physiology, 2011, 226, 2316-2328.	2.0	145
4	Identification of mammalian-like purple acid phosphatases in a wide range of plants. Gene, 2000, 250, 117-125.	1.0	141
5	A delicate balance â€“ The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics. Biochemical Pharmacology, 2019, 162, 250-261.	2.0	135
6	The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia, 2009, 23, 1417-1425.	3.3	132
7	Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Clinical Cancer Research, 2019, 25, 6815-6826.	3.2	115
8	GATA1, Cytidine Deaminase, and the High Cure Rate of Down Syndrome Children With Acute Megakaryocytic Leukemia. Journal of the National Cancer Institute, 2005, 97, 226-231.	3.0	107
9	High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. Blood, 2002, 99, 2992-2996.	0.6	104
10	Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy, 2017, 2, 17012.	7.1	104
11	Down syndrome, drug metabolism and chromosome 21. Pediatric Blood and Cancer, 2005, 44, 33-39.	0.8	99
12	Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood, 2006, 107, 1570-1581.	0.6	99
13	Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduction and Targeted Therapy, 2020, 5, 288.	7.1	98
14	Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood, 2004, 104, 1588-1589.	0.6	95
15	The Phosphatase MKP1 Is a Transcriptional Target of p53 Involved in Cell Cycle Regulation. Journal of Biological Chemistry, 2003, 278, 41059-41068.	1.6	92
16	Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199. Leukemia, 2014, 28, 1557-1560.	3.3	87
17	Down Syndrome and Malignancies: A Unique Clinical Relationship. Journal of Molecular Diagnostics, 2009, 11, 371-380.	1.2	86
18	RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood, 2009, 114, 2744-2752.	0.6	81

#	Article	IF	Citations
19	The Role of Cytidine Deaminase and GATA1 Mutations in the Increased Cytosine Arabinoside Sensitivity of Down Syndrome Myeloblasts and Leukemia Cell Lines. Cancer Research, 2004, 64, 728-735.	0.4	78
20	Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51. PLoS ONE, 2013, 8, e79106.	1.1	76
21	Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia. Clinical Cancer Research, 2010, 16, 5499-5510.	3.2	71
22	Improved outcomes for myeloid leukemia of Down syndrome: a report from the Childrenâ€™s Oncology Group AAML0431 trial. Blood, 2017, 129, 3304-3313.	0.6	71
23	A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemia Pathogenesis. Cancer Cell, 2018, 34, 707-723.e7.	7.7	68
24	Prenatal origin of childhood acute lymphoblastic leukemia, association with birth weight and hyperdiploidy. Leukemia, 2008, 22, 1692-1697.	3.3	67
25	Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells. Biochemical and Biophysical Research Communications, 2013, 434, 95-101.	1.0	67
26	MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome. Blood, 2015, 125, 1292-1301.	0.6	66
27	Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome. Blood, 2009, 114, 2753-2763.	0.6	65
28	Transcriptional regulation of the human cystathionine Î²-synthase â˜†1b basal promoter: synergistic transactivation by transcription factors NF-Y and Sp1/Sp3. Biochemical Journal, 2001, 357, 97-105.	1.7	64
29	Association between prenatal pesticide exposures and the generation of leukemia-associated T(8;21). Pediatric Blood and Cancer, 2007, 49, 624-628.	0.8	57
30	Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy and Behavior, 2011, 21, 27-30.	0.9	53
31	Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia. Haematologica, 2019, 104, 2225-2240.	1.7	53
32	Structure and Regulation of the Murine Reduced Folate Carrier Gene. Journal of Biological Chemistry, 2005, 280, 5588-5597.	1.6	49
33	Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells. PLoS ONE, 2011, 6, e17138.	1.1	47
34	Transcriptional regulation of the cystathionine-Î²-synthase gene in Down syndrome and nonâ€“Down syndrome megakaryocytic leukemia cell lines. Blood, 2003, 101, 1551-1557.	0.6	46
35	The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. Leukemia, 2008, 22, 521-529.	3.3	46
36	Age-Related Loss of the DNA Repair Response Following Exposure to Oxidative Stress. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 427-434.	1.7	44

#	Article	IF	Citations
37	Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. Signal Transduction and Targeted Therapy, 2020, 5, 17.	7.1	43
38	Physical and Functional Interactions between USF and Sp1 Proteins Regulate Human Deoxycytidine Kinase Promoter Activity. Journal of Biological Chemistry, 2003, 278, 49901-49910.	1.6	42
39	Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells. Scientific Reports, 2017, 7, 41950.	1.6	42
40	Inhibition of <scp>XPO</scp>1 enhances cell death induced by <scp>ABT</scp>â€199 in acute myeloid leukaemia via Mclâ€1. Journal of Cellular and Molecular Medicine, 2018, 22, 6099-6111.	1.6	42
41	H₂O₂/Peroxynitrite-Activated Hydroxamic Acid HDAC Inhibitor Prodrugs Show Antileukemic Activities against AML Cells. ACS Medicinal Chemistry Letters, 2018, 9, 635-640.	1.3	42
42	CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. Journal of Hematology and Oncology, 2014, 7, 53.	6.9	41
43	Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia. Leukemia Research, 2019, 84, 106180.	0.4	41
44	Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer. PLoS ONE, 2012, 7, e52095.	1.1	41
45	Transcriptional regulation of the human cystathionine Î²-synthase â^'1b basal promoter: synergistic transactivation by transcription factors NF-Y and Sp1/Sp3. Biochemical Journal, 2001, 357, 97.	1.7	40
46	Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochemical Pharmacology, 2018, 148, 13-26.	2.0	38
47	The Prenatal Origin of Childhood Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 2004, 45, 19-25.	0.6	37
48	Transcriptional Regulation of Cell-specific Expression of the Human Cystathionine Î²-Synthase Gene by Differential Binding of Sp1/Sp3 to the â^'1b Promoter. Journal of Biological Chemistry, 2001, 276, 43570-43579.	1.6	36
49	Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage. Molecular Oncology, 2015, 9, 409-421.	2.1	35
50	Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Oncotarget, 2016, 7, 34785-34799.	0.8	35
51	CUDCâ€907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action. Journal of Cellular and Molecular Medicine, 2020, 24, 7239-7253.	1.6	35
52	Coimmobilization of glucoamylase and glucose isomerase by molecular deposition technique for one-step conversion of dextrin to fructose. Journal of Biotechnology, 1999, 67, 33-40.	1.9	33
53	Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells. Journal of Medicinal Chemistry, 2016, 59, 7974-7990.	2.9	33
54	Risk for leukemia in infants without down syndrome who have transient myeloproliferative disorder. Journal of Pediatrics, 2006, 148, 687-689.	0.9	32

#	Article	IF	Citations
55	Celastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cells. International Journal of Molecular Medicine, 2010, 25, 465-70.	1.8	32
56	Telomerase as an Important Target of Androgen Signaling Blockade for Prostate Cancer Treatment. Molecular Cancer Therapeutics, 2010, 9, 2016-2025.	1.9	32
57	Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo. Cancer Biology and Therapy, 2015, 16, 1784-1793.	1.5	32
58	Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. Cancer Letters, 2015, 356, 656-668.	3.2	32
59	Panobinostat Synergistically Enhances the Cytotoxic Effects of Cisplatin, Doxorubicin or Etoposide on High-Risk Neuroblastoma Cells. PLoS ONE, 2013, 8, e76662.	1.1	32
60	Roles of USF, Ikaros and Sp proteins in the transcriptional regulation of the human reduced folate carrier B promoter. Biochemical Journal, 2004, 383, 249-257.	1.7	30
61	Synergistic regulation of human cystathionine-Î²-synthase-1b promoter by transcription factors NF-YA isoforms and Sp1. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2002, 1579, 73-80.	2.4	29
62	Targeting mitochondrial respiration for the treatment of acute myeloid leukemia. Biochemical Pharmacology, 2020, 182, 114253.	2.0	29
63	Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Oncotarget, 2017, 8, 44295-44311.	0.8	29
64	Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatric Blood and Cancer, 2014, 61, 1767-1773.	0.8	28
65	Natural plant flavonoid apigenin directly disrupts Hsp90/Cdc37 complex and inhibits pancreatic cancer cell growth and migration. Journal of Functional Foods, 2015, 18, 10-21.	1.6	28
66	Effects of EPHX1, SCN1A and CYP3A4 genetic polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Research, 2013, 107, 231-237.	0.8	27
67	Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells. Oncotarget, 2017, 8, 6319-6329.	0.8	26
68	Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation. Cancers, 2020, 12, 2400.	1.7	26
69	A userâ€™s guide to lorlatinib. Critical Reviews in Oncology/Hematology, 2020, 151, 102969.	2.0	26
70	Transcription factor GATA-1 and Down syndrome leukemogenesis. Leukemia and Lymphoma, 2006, 47, 986-997.	0.6	25
71	Prognosis and management of acute myeloid leukemia in patients with Down syndrome. Expert Review of Hematology, 2014, 7, 831-840.	1.0	24
72	Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Letters, 2014, 348, 20-28.	3.2	24

#	Article	IF	Citations
73	The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Haematologica, 2021, 106, 1262-1277.	1.7	24
74	The GATA site-dependent hemogen promoter is transcriptionally regulated by GATA1 in hematopoietic and leukemia cells. Leukemia, 2006, 20, 417-425.	3.3	23
75	Prognostic Role of the Reduced Folate Carrier, the Major Membrane Transporter for Methotrexate, in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group. Clinical Cancer Research, 2007, 13, 451-457.	3.2	23
76	Effects of 5â€² untranslated region diversity on the posttranscriptional regulation of the human reduced folate carrier. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2007, 1769, 131-138.	2.4	22
77	Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine. Oncology Reports, 2017, 37, 3377-3386.	1.2	22
78	The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML. Blood Cancer Journal, 2021, 11, 111.	2.8	22
79	Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatric Blood and Cancer, 2012, 59, 1245-1251.	0.8	21
80	Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors. Oncotarget, 2016, 7, 57171-57185.	0.8	21
81	Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia. Blood, 2021, 137, 3641-3655.	0.6	20
82	Transcriptional Regulation of the Human Reduced Folate Carrier in Childhood Acute Lymphoblastic Leukemia Cells. Clinical Cancer Research, 2006, 12, 608-616.	3.2	19
83	An unexpected protein interaction promotes drug resistance in leukemia. Nature Communications, 2017, 8, 1547.	5.8	19
84	Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group. Oncogene, 2008, 27, 4933-4942.	2.6	18
85	The critical role of myostatin in differentiation of sheep myoblasts. Biochemical and Biophysical Research Communications, 2012, 422, 381-386.	1.0	18
86	Transcriptional regulation of the human reduced folate carrier promoter C: synergistic transactivation by Sp1 and C/EBP Î² and identification of a downstream repressor. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2005, 1727, 45-57.	2.4	17
87	Unique clinical and biological features of leukemia in Down syndrome children. Expert Review of Hematology, 2010, 3, 175-186.	1.0	17
88	Overexpression of GATA1 Confers Resistance to Chemotherapy in Acute Megakaryocytic Leukemia. PLoS ONE, 2013, 8, e68601.	1.1	17
89	COVIDâ€19 and childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28400.	0.8	17
90	The impact of V30A mutation on transthyretin protein structural stability and cytotoxicity against neuroblastoma cells. Archives of Biochemistry and Biophysics, 2013, 535, 120-127.	1.4	16

#	Article	IF	Citations
91	Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia . Cancer Management and Research, 2019, Volume 11, 3197-3213.	0.9	16
92	Acute Megakaryoblastic Leukemia Without GATA1 Mutation After Transient Myeloproliferative Disorder in an Infant Without Down Syndrome. Journal of Clinical Oncology, 2011, 29, e230-e233.	0.8	15
93	Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia. American Journal of Translational Research (discontinued), 2016, 8, 3893-3902.	0.0	13
94	Knockdown of endogenous myostatin promotes sheep myoblast proliferation. In Vitro Cellular and Developmental Biology - Animal, 2014, 50, 94-102.	0.7	12
95	Concomitant Use of Panobinostat and Reirradiation in Progressive DIPG: Report of 2 Cases. Journal of Pediatric Hematology/Oncology, 2017, 39, e332-e335.	0.3	12
96	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. Cancer, 2020, 126, 4800-4805.	2.0	12
97	Immobilization of glucose isomerase and its application in continuous production of high fructose syrup. Applied Biochemistry and Biotechnology, 1998, 69, 203-215.	1.4	11
98	Transcriptional regulation of the human reduced folate carrier A1/A2 promoter: Identification of critical roles for the USF and GATA families of transcription factors. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2005, 1731, 115-124.	2.4	11
99	A Unique Role of GATA1s in Down Syndrome Acute Megakaryocytic Leukemia Biology and Therapy. PLoS ONE, 2011, 6, e27486.	1.1	11
100	Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells. Oncology Reports, 2014, 32, 2789-2794.	1.2	10
101	Venetoclax enhances DNA damage induced by XPO1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia. Journal of Cellular and Molecular Medicine, 2022, 26, 2646-2657.	1.6	9
102	â€œFLippingâ€•the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors. Cancers, 2022, 14, 3398.	1.7	9
103	Co-immobilization of cellulase and glucose isomerase by molecular deposition technique. Biotechnology Letters, 1997, 11, 359-361.	0.5	8
104	Targeting histone deacetylases (HDACs) and Wee1 for treating highâ€•risk neuroblastoma. Pediatric Blood and Cancer, 2015, 62, 52-59.	0.8	8
105	Gene Signature of High White Blood Cell Count in B-Precursor Acute Lymphoblastic Leukemia. PLoS ONE, 2016, 11, e0161539.	1.1	8
106	ONC201 shows promise in AML treatment. Cell Cycle, 2018, 17, 277-277.	1.3	7
107	Immobilization of glucose isomerase and its application in continuous production of high fructose syrup. Applied Biochemistry and Biotechnology, 1998, 69, 17-29.	1.4	6
108	The paradox of Myeloid Leukemia associated with Down syndrome. Biochemical Pharmacology, 2022, 201, 115046.	2.0	6

#	Article	IF	Citations
109	Synergistic antitumor interactions between gemcitabine and clofarabine in human pancreatic cancer cell lines. Molecular Medicine Reports, 2011, 5, 734-8.	1.1	5
110	Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo. Targeted Oncology, 2019, 14, 351-364.	1.7	5
111	A compound combination screening approach with potential to identify new treatment options for paediatric acute myeloid leukaemia. Scientific Reports, 2020, 10, 18514.	1.6	5
112	Role of USF1 in the differential expression of the human deoxycytidine kinase gene in acute myeloid leukemia. Leukemia, 2005, 19, 677-679.	3.3	4
113	Monozygotic twins with neuroblastoma MS have a similar molecular profile: a case of twin-to-twin metastasis. British Journal of Cancer, 2019, 121, 890-893.	2.9	4
114	Simultaneous cotargeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia. Signal Transduction and Targeted Therapy, 2019, 4, 44.	7.1	4
115	Expression and purification of recombinant NRL-Hsp90Î± and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening. Protein Expression and Purification, 2013, 92, 119-127.	0.6	2
116	When it comes to drug access, should children be considered small adults? Countering coverage denials of FLT3 inhibitors in children with FLT3â€ITD AML. Pediatric Blood and Cancer, 2021, 68, e29278.	0.8	2
117	Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia. Blood, 2018, 132, 1361-1361.	0.6	2
118	Binding of Released Bim to Mcl-1 Is Responsible for Resistance to ABT-199 Which Can be Overcome By Combination with Daunorubicin or Cytarabine in Acute Myeloid Leukemia Cells. Blood, 2015, 126, 1265-1265.	0.6	2
119	Co-immobilization of glucoamylase and glucose oxidase based on molecular deposition. Biotechnology Letters, 1996, 10, 861-866.	0.5	1
120	Inhibition of CHK1 Enhances Cell Death Induced By the Bcl-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells. Blood, 2015, 126, 2469-2469.	0.6	1
121	Down syndrome and leukemia: A model of leukemogenesis and cure. International Journal on Disability and Human Development, 2008, 7, .	0.2	0
122	Etiology of Leukemia in Children with Down Syndrome. , 2016, , 89-108.		0
123	MAP4K1 expression is a novel resistance mechanism and independent prognostic marker in AML-but can be overcome via targeted inhibition. EBioMedicine, 2021, 70, 103488.	2.7	0
124	Down Syndrome and Acute Myeloid Leukemia: An Unique Genetic Sensitivity to Chemotherapy. , 2010, , 109-122.		0
125	Targeting The Wee1 Kinase With MK-1775 For Treatment Of Acute Myeloid Leukemia In The Down Syndrome Population. Blood, 2013, 122, 3836-3836.	0.6	0
126	Combination of Venetoclax and CUDC-907 Shows Superior Antileukemic Activity Against Acute Myeloid Leukemia Ex Vivo. Blood, 2016, 128, 1571-1571.	0.6	0

#	Article	IF	Citations
127	Venetoclax Synergistically Enhances the Antileukemic Activity of Imipridone ONC213, a Novel Imipridone ONC201 Analog, in Acute Myeloid Leukemia. Blood, 2018, 132, 3936-3936.	0.6	0
128	Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment. Blood, 2020, 136, 20-20.	0.6	0